<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556400</url>
  </required_header>
  <id_info>
    <org_study_id>080022</org_study_id>
    <secondary_id>08-CH-0022</secondary_id>
    <nct_id>NCT00556400</nct_id>
  </id_info>
  <brief_title>Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones</brief_title>
  <official_title>Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the role of oral contraceptive pills in managing uterine bleeding in&#xD;
      women who have low blood platelet counts as a result of aplastic anemia. Oral contraceptive&#xD;
      pills have been shown to be effective in managing uterine bleeding in healthy women, but the&#xD;
      effects have not been thoroughly studied in women who have low platelet counts. The purpose&#xD;
      of the study is to determine whether oral contraceptive pills are a useful complement to&#xD;
      platelet transfusions in women with aplastic anemia and uterine bleeding.&#xD;
&#xD;
      Volunteers for this study must be women between 12 and 55 years of age who have been&#xD;
      diagnosed with aplastic anemia (with a platelet count of less than 50,000/microliter) and&#xD;
      currently have active uterine bleeding. Candidates must not be pregnant or breastfeeding,&#xD;
      must have a uterus and at least one functioning ovary, and must be willing to use nonhormonal&#xD;
      methods of birth control (such as condoms or a diaphragm) for the duration of the study. On&#xD;
      the first visit, candidates will be screened with a complete medical history (including&#xD;
      obstetric and gynecological history) and will undergo a physical examination, a pelvic exam&#xD;
      and a pelvic ultrasound. Blood and urine samples will also be taken on this first visit.&#xD;
&#xD;
      The study will last approximately two weeks. Participants will be asked to monitor their&#xD;
      medication doses and severity of bleeding during the course of the study. After the first&#xD;
      visit, participants will be separated into two randomized groups and will receive either one&#xD;
      tablet of oral contraceptive or a placebo twice daily, to be taken 12 hours apart at the same&#xD;
      times each day. Participants will also receive platelet transfusions as needed to ensure that&#xD;
      their platelet counts remain over 20,000/microliter. After seven days, researchers will&#xD;
      assess participants' uterine bleeding and all participants will be given oral contraceptives&#xD;
      in the second week of the study. Participants whose bleeding has decreased will receive only&#xD;
      one tablet; participants who still have moderate to severe uterine bleeding will receive two&#xD;
      tablets. A final assessment will be performed on day 14 of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low platelet counts can occur as a result of blood diseases like bone marrow failure, or from&#xD;
      undergoing procedures such as chemotherapy treatment or stem cell transplantation. A major&#xD;
      complication of low platelet counts in reproductive aged women is uterine bleeding, which can&#xD;
      be life threatening. Sometimes this bleeding begins with a normal menstrual cycle but may&#xD;
      start unexpectedly. In either instance, stopping uterine bleeding not only requires blood&#xD;
      products including platelets but also hormonal treatments.&#xD;
&#xD;
      The hormones estrogen or progesterone can aid in this setting presumably by promoting&#xD;
      endometrial angiogenesis. Continuous oral contraceptive pills (OCP) have been shown to be&#xD;
      very effective in the management of heavy menstrual bleeding in healthy women, but few&#xD;
      studies have been carried out in women with low platelet counts. Moreover, they have few&#xD;
      side-effects and are contraceptive. High-dose intravenous Premarin is also useful but only&#xD;
      for a couple of days after which heavy bleeding will ensue. Progestin hormones are similarly&#xD;
      effective and are also contraceptive.&#xD;
&#xD;
      Oral contraceptive pills are routinely used to control uterine bleeding in thrombocytopenia&#xD;
      secondary to bone marrow failure, chemotherapy and/or stem cell transplantation, during&#xD;
      episodes of severe thrombocytopenia. There are no current data supporting whether the use of&#xD;
      hormonal management is necessary in addition to platelet transfusion. We expect to show that&#xD;
      using continuous OCP in addition to having platelet transfusions will result in a better and&#xD;
      more rapid control of uterine bleeding than having platelet transfusions only.&#xD;
&#xD;
      Eligible subjects will be hemodynamically stable, menstruating women aged 12-55, who have&#xD;
      bone marrow failure, or are undergoing chemotherapy and/or stem cell transplantation for&#xD;
      other diseases with platelet levels less than 50,000/ microliter and present with heavy&#xD;
      menstrual bleeding which is expected to last at least 2 weeks. Subjects will be randomized to&#xD;
      either continuous OCP (Lo-ovral) 1 tablet twice daily or placebo twice daily for one week.&#xD;
      All subjects will receive platelet transfusions to keep platelet levels above 20,000 per&#xD;
      microliter throughout the study. After one week, all subjects who continue to bleed will&#xD;
      receive continuous OCP 1 tablet twice daily. Those who have stopped bleeding will receive&#xD;
      continuous OCP 1 tablet daily. Treatments will be compared for the proportion who stop&#xD;
      vaginal bleeding 7 and 14 days after starting treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination because of insufficient accrual.&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stop Vaginal Bleeding or Spotting.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion Who Stop Uterine Bleeding by Day 14.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Bleeding Days During the First 7 Days.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Menorrhagia</condition>
  <condition>Amenorrhea</condition>
  <arm_group>
    <arm_group_label>Lo-ovral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet of lo-ovral is administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill was provided as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lo-Ovral Oral Contraceptive Pills</intervention_name>
    <arm_group_label>Lo-ovral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - sugar pill</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Women aged 12-55 years who have a uterus and at least one functioning ovary.&#xD;
&#xD;
        Women with any active uterine bleeding more than spotting&#xD;
&#xD;
        Diagnosed with bone marrow failure, and other disease that require treatment with&#xD;
        chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters&#xD;
        at study entry&#xD;
&#xD;
        Do not desire pregnancy for the duration of the study.&#xD;
&#xD;
        Willing and able to give informed consent.&#xD;
&#xD;
        Willing and able to comply with study requirements.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Age less than 12 years&#xD;
&#xD;
        Postmenopausal women&#xD;
&#xD;
        Hormone level in menopausal range: Follicle Stimulating Hormone greater than 40 IU/L, E (2)&#xD;
        less than 20 pg/ml&#xD;
&#xD;
        History of liver disease that precludes OCP use&#xD;
&#xD;
        History of thrombosis, thromboembolism and/or thrombophilia.&#xD;
&#xD;
        Currently on 2 or more tablets of any oral contraceptive pills per day at study entry&#xD;
&#xD;
        Having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or&#xD;
        having depo medroxyprogesterone acetate injection in the past 90 days&#xD;
&#xD;
        Leuprolide acetate injection in the past 30 days&#xD;
&#xD;
        Smoker over the age of 35&#xD;
&#xD;
        Women with estrogen dependent tumor e.g. breast cancer.&#xD;
&#xD;
        Pregnancy.&#xD;
&#xD;
        Underlying sickle cell anemia&#xD;
&#xD;
        Women who are taking chemotherapeutic agents known to cause ovarian failure such as&#xD;
        alkylating agents&#xD;
&#xD;
        Allergy to any medication in this protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Stratton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Amsterdam A, Jakubowski A, Castro-Malaspina H, Baxi E, Kauff N, Krychman M, Stier E, Castiel M. Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004 Aug;34(4):363-6.</citation>
    <PMID>15195079</PMID>
  </reference>
  <reference>
    <citation>Girling JE, Rogers PA. Recent advances in endometrial angiogenesis research. Angiogenesis. 2005;8(2):89-99. Epub 2005 Oct 7. Review.</citation>
    <PMID>16211359</PMID>
  </reference>
  <reference>
    <citation>Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007 Mar;22(3):635-43. Epub 2007 Jan 4.</citation>
    <PMID>17204526</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <results_first_submitted>May 21, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2013</results_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Bleeding</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Aplastic Anemia</keyword>
  <keyword>Oral Contraceptive Pills</keyword>
  <keyword>Menorrhagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lo-ovral</title>
          <description>1 tablet of lo-ovral is administered twice a day</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lo-ovral</title>
          <description>1 tablet of lo-ovral is administered twice a day</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stop Vaginal Bleeding or Spotting.</title>
        <time_frame>1 week</time_frame>
        <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lo-ovral</title>
            <description>1 tablet of lo-ovral is administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
          </group>
        </group_list>
        <measure>
          <title>Stop Vaginal Bleeding or Spotting.</title>
          <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion Who Stop Uterine Bleeding by Day 14.</title>
        <time_frame>2 weeks</time_frame>
        <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lo-ovral</title>
            <description>1 tablet of lo-ovral is administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion Who Stop Uterine Bleeding by Day 14.</title>
          <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Bleeding Days During the First 7 Days.</title>
        <time_frame>1 week</time_frame>
        <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lo-ovral</title>
            <description>1 tablet of lo-ovral is administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Bleeding Days During the First 7 Days.</title>
          <population>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed. No adverse events data was collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Pamela Stratton</name_or_title>
      <organization>NICHD</organization>
      <phone>301 496-9079</phone>
      <email>strattop@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

